Incoatec and Bruker AXS Announce IuS, a User-Friendly High-Brilliance X-ray Microsource; Brightest Sealed-Tube X-ray Source For a Wide Variety of X-ray Analysis Applications.

LEUVEN, Belgium -- At the ECM 23 (European Crystallographic Meeting), Incoatec GmbH from Hamburg, Germany, an innovative manufacturer of X-ray optics, and Bruker AXS Inc., a leading global provider of advanced X-ray solutions for life and advanced materials sciences, today launch their novel IuS(TM) X-ray microsource, the brightest sealed-tube X-ray generator ever. IuS is an optimized, high-brilliance X-ray source incorporating a 30 W micro-focus sealed tube together with high-performance Montel multilayer X-ray optics. The IuS offers numerous benefits: it has no moving parts, has a very long lifetime without maintenance, is extremely stable, does not require water-cooling, is easy to replace, and has low cost of ownership comparable to common sealed tubes. The IuS is significantly more intense than previous microfocus source designs and provides a photon intensity which is up to five times higher than a conventional sealed tube system that is comparable to a conventional 5.4 kW-class rotating anode generator. The IuS is thus a highly affordable replacement for older high-power rotating anode sources, offering high performance together with customer convenience and low operating costs.

"During the joint Incoatec and Bruker AXS development of the IuS, data quality was the key objective. Integrated into a single crystal diffraction setup, data was collected on insulin with 10 seconds of exposure per frame, resulting in a diffraction signal down to 1.5 A resolution. Due to the high IuS stability, SAD phasing of insulin was possible down to 2.2 A. The data we collected was better than data from a conventional 5.4 kW rotating anode system," stated Dr. Carsten Michaelsen, Managing Director of Incoatec.

"For our NANOSTAR(TM), Bruker AXS Small Angle X-ray Scattering instrument, there is a factor of five intensity gain of the IuS over a conventional sealed-tube setup. This intensity gain is the optimum achievable value as predicted from ray tracing calculations," commented Dr. Frank Burgazy, Executive Vice President of Bruker AXS.

The IuS can be integrated into a variety of X-ray analytical systems for a range of applications. Its compact design makes the IuS an attractive component for many academic and industrial materials research organizations to upgrade their existing X-ray analytical instruments to cutting-edge performances.

For more information on ECM23, please visit www.ecm23.be

ABOUT INCOATEC

Incoatec GmbH offers the newest generation of multilayer optics used in X-ray analytic equipment and synchrotron applications. Incoatec components and subunits enable scientists to form X-ray beams according to their individual requirements in various applications such as protein crystallography, high-resolution X-ray diffractometry and X-ray fluorescence spectrometry. Incoatec manufactures ultra-high precision optics using highly modern bending and coating technology. The company's advanced current technology, as well as their continuous developments in partnerships with industry and with research centers, enable Incoatec to meet cutting-edge customer requirements worldwide. For further information, please visit www.incoatec.de

ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

Bruker BioSciences Corporation in Billerica, Massachusetts is the parent company of Bruker AXS Inc., Bruker Daltonics Inc. and Bruker Optics, Inc. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis tools. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry, and also offers a broad line of chemical, biological, radiological and nuclear (CBRN) detection products for homeland security. Bruker Optics is a leading developer, manufacturer and provider of research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technology. For more information, please visit www.bruker-biosciences.com

CAUTIONARY STATEMENT OF BRUKER BIOSCIENCES

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, exposure to currency fluctuations, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2005, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.